Ipamorelin FAQ: Risks, Side Effects, CJC-1295 & Timing
What are the risks of ipamorelin?
The largest risk is the unknown: ipamorelin has no long-term human safety data, and its only Phase 2 trial (n=114) missed its primary endpoint [3]. Cited cautions cluster around the GH axis — theoretical IGF-1/proliferation concerns, glucose dysregulation, and a class-level cardiac signal from a related compound [6]. Most material is also unregulated research-grade of unverified purity.
What are the downsides of ipamorelin?
The honest downside is that the human evidence is thin and mostly negative: one failed Phase 2 trial for bowel recovery (25.3 h vs 32.6 h, p=0.15) [3], no approved use, and no long-term safety database. Reported side effects are mostly minor and transient — flush, injection-site reactions, occasional puffiness — but they are anecdotal, not measured outcomes.
Does ipamorelin cause cancer?
No ipamorelin study has shown it causes cancer, and none has tested the question in humans. The concern is theoretical and mechanistic: GH stimulates IGF-1, a mitogen that promotes cell growth [1]. Raising GH pulses could in principle accelerate a pre-existing or hidden tumor. This is a class-level caution, not an observed finding from any ipamorelin study.
What are the side effects of CJC-1295 and ipamorelin?
There is no controlled human side-effect data for the combination. Reported side effects from research-use communities — facial flush, injection-site irritation, tingling, mild water retention, hunger after injection — are anecdotal, not clinical. The single Phase 2 ipamorelin trial recorded adverse events comparable to placebo over 7 days [3], but that is short-term, single-agent, IV data only.
Does ipamorelin affect cortisol or prolactin?
Not meaningfully — that is its defining trait. In the 1998 characterization, ipamorelin released GH potently in rat cells, rats, and swine, yet did not raise ACTH or cortisol above the GHRH baseline even at doses more than 200-fold above its GH ED50 [1]. This selectivity distinguishes it from older GHRPs like GHRP-6 and GHRP-2, which do raise cortisol and prolactin.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) to release a pulse of growth hormone [1]. Its signature is selectivity: GH release without raising cortisol or prolactin. It is a research peptide, never approved as a drug, with a human terminal half-life of about 2 hours [2].
What does ipamorelin do for you?
In studies, ipamorelin triggers a single discrete pulse of growth hormone peaking near 40 minutes after dosing [2], and in rats it drove dose-dependent bone growth [4]. Community users report better sleep and recovery, but those are anecdotal, not clinical. The one human efficacy trial — for bowel recovery — did not succeed [3]. There is no proven human benefit.
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic five-amino-acid chain, formula C38H49N9O5, about 711.85 Da, CAS 170851-70-4. Built from GHRP-1 by removing a central dipeptide, it resists enzymatic breakdown via its Aib residue and D-amino acids [1]. It is a selective GHS-R1a (ghrelin-receptor) agonist that releases growth hormone — not an endogenous human peptide.
Does ipamorelin reduce belly fat?
No human study shows ipamorelin reduces belly fat. The closest data is a 2024 ferret study where IP ipamorelin (1-3 mg/kg) reduced chemotherapy-induced weight loss by about 24%, via a peripheral mechanism [5] — that is protection against weight loss, not fat reduction. Community reports of a leaner look are anecdotal and confounded by diet and training.
Why is ipamorelin being discontinued?
Ipamorelin's clinical program stalled because it failed, not merely paused. Its only Phase 2 trial, for postoperative ileus, missed its primary endpoint (25.3 h vs 32.6 h, p=0.15) and no further development followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access.
What does CJC-1295 and ipamorelin do?
The pairing combines two arms of GH control: CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor agonist). In animal models, GHRH-analog plus GHRP synergy produces GH peaks greater than the sum of each alone [9]. In humans, no controlled trial of the combination exists for any outcome — the mechanism is documented, the human results are not.
Does ipamorelin increase IGF-1?
Not always, and not reliably in short studies. In the 15-day rat bone-growth study, ipamorelin drove bone growth with no measured change in total IGF-1 [4], suggesting a partly local GH-pulse effect. In diabetic mice, IGF-1 was actually suppressed despite GH hypersecretion [8]. Sustained IGF-1 elevation is mechanistically plausible but not a consistent finding in the rodent data.
How does CJC-1295 ipamorelin work?
Ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary cells to release GH [1]; CJC-1295 activates the separate GHRH receptor. Because endogenous GHRH is required for full GHRP activity — GHRP-6 activity is attenuated when GHRH is blocked [10] — pairing a GHRH analog with a ghrelin-receptor agonist produces synergistic GH release in animal models [9].
How much CJC-1295 ipamorelin should I take?
This site does not provide a dose. No peer-reviewed human dosing exists for the combination; community subcutaneous 'stack' protocols have no controlled-trial basis and are anecdotal, not recommended [3]. The only human ipamorelin dosing in the literature is IV research dosing under supervision [2], none of it self-administered. No number here is a recommendation.
Does CJC-1295 ipamorelin work?
For raising GH in animals, the synergy is real — GHRH-analog plus GHRP exceeds additive GH release in controlled rat work [9]. For human outcomes like fat loss or recovery, there is no controlled trial of the combination, and the one human ipamorelin trial that ran (for bowel recovery) failed [3]. The pharmacology is established; the human outcome claims are not.
How to reconstitute CJC-1295 ipamorelin 5mg?
As a general research-handling note, lyophilized peptide is reconstituted with bacteriostatic water for laboratory use, and reconstituted solution is kept refrigerated because peptides degrade with heat and freeze-thaw. This is a handling observation from the research-supply literature, not a clinical preparation step, not a dose, and not guidance for human use. No self-administration protocol is provided.
How long does ipamorelin stay in your system?
Terminal half-life in healthy human volunteers is about 2 hours (IV) [2]. Using the pharmacology convention of roughly four to five half-lives for near-complete elimination, the parent peptide clears within about 8-10 hours. Anti-doping detection is a separate question — accredited labs detect ipamorelin in urine, and detection windows differ from clearance. The full read is on the how long does ipamorelin stay in your system page.
Does ipamorelin make you hungry?
Some users report increased hunger after injection, which fits the mechanism — ipamorelin acts on the ghrelin receptor, and ghrelin is the hunger hormone [1]. A 2026 critical review flags ipamorelin among GH-secretagogues promoted in sport, noting safety concerns in uncontrolled use [13]. The appetite reports are anecdotal; community accounts describe the effect as milder than GHRP-6.
Will I gain weight on ipamorelin?
No human study answers this. In rats, an oral ipamorelin-derived analog produced body-weight gain over 14 days through sustained GH-axis activation [7], and the ghrelin-receptor mechanism carries a class-level appetite and adiposity signal [3]. Community reports vary. Any weight change is unstudied in humans at research-use exposure and confounded by diet and training.
Does ipamorelin increase appetite?
Mechanistically, yes it can — it activates the ghrelin receptor, the same receptor the hunger hormone uses [1]. A 2026 sport-medicine review notes appetite among the class-level effects of GH-secretagogue peptides used outside clinical settings [13]. Reported real-world appetite increase is described as milder than GHRP-6 but still present for some users; these accounts are anecdotal.
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin receptor (GHS-R1a) to release a single pulse of growth hormone [1], peaking near 40 minutes after dosing in humans [2]. Its hallmark is doing this without raising cortisol or prolactin [1]. In rats it produced dose-dependent bone growth [4]; in humans, no efficacy outcome has been demonstrated [3].
How long does it take for ipamorelin to work?
Pharmacologically, fast: the GH pulse peaks near 40 minutes after an IV dose in humans, and the peptide clears with a roughly 2-hour half-life [2]. That is the measured GH response, not a human outcome timeline. Community reports of sleep changes within one to two weeks are anecdotal, not clinical, and no controlled human trial has measured a benefit timeline [3].